IPSC beat EPS expectations by 19.25%
Aug 08, 2024, 12:34 PM
0.00%
What does IPSC do
Century Therapeutics, headquartered in Philadelphia, specializes in developing off-the-shelf allogeneic cell therapies for cancer, utilizing an advanced platform featuring iPSCs and CRISPR technology. Their key products, including CNTY-101 and CNTY-102, target B-cell lymphoma, with other candidates aimed at solid tumors and leukemia.
Century Therapeutics (IPSC) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Century Therapeutics's actual EPS was -$0.38, beating the estimate of -$0.47 per share, resulting in a 19.25% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.